Amgen's Imlygic becomes first re-engineered virus to earn FDA approval as a cancer fighter

Amgen's ($AMGN) Imlygic became the first genetically modified oncolytic viral therapy to earn FDA approval. It's indicated to treat recurrent melanoma following surgery. Imlygic is a modified herpes simplex type 1 virus that replicates within tumors and releases a protein called granulocyte-macrophage colony-stimulating factor. GM-CSF kills tumors, which results in the spread of tumor-derived antigens that may stimulate the immune system, along with GM-CSF itself. Interestingly enough, Amgen says the precise mechanism of action is unknown, a sure sign that the medicine lies at the frontiers of drug delivery. Release | More from FierceBiotech

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…